Royal Bank of Canada
CRXT

Royal Bank of Canada’s Clarus Therapeutics Holdings, Inc. Common Stock CRXT Stock Holding History

Royal Bank of Canada’s Portfolio CRXT Stock Details CRXT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-500
Closed -$1K – 8149
2022
Q1 		$1K Buy
+500
New +$635 ﹤0.01% 7676
2021
Q4 		– Sell
-200
Closed -$1K – 8166
2021
Q3 		$1K Buy
200
+99
+98% +$890 ﹤0.01% 7565
2021
Q2 		$1K Sell
101
-1,746
-95% -$17.6K ﹤0.01% 7407
2021
Q1 		$19K Buy
+1,847
New +$18.6K ﹤0.01% 6468

Other funds holding CRXT

BCL
Bracebridge Capital LLC Boston, Massachusetts $3.73B AUM 33.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CAN
Cetera Advisor Networks El Segundo, California $20.2B AUM 22.31% 1-Year Est. Return
PIA
Powell Investment Advisors Miami, Florida $317M AUM 26.57% 1-Year Est. Return

Royal Bank of Canada's CRXT Position: Q2 2022 in Review

Royal Bank of Canada sold out of Clarus Therapeutics Holdings, Inc. Common Stock (CRXT) in Q2 2022, closing a stake of 500 shares — an estimated $1K sold.

Royal Bank of Canada first reported a position in CRXT in Q1 2021 and held it in 4 quarters. The position peaked at $19K in Q1 2021. 25 funds tracked by Wall St. Rank hold CRXT as of Q2 2022.

  • Royal Bank of Canada reported no remaining Clarus Therapeutics Holdings, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Royal Bank of Canada sold 500 Clarus Therapeutics Holdings, Inc. Common Stock shares in Q2 2022, an estimated $1K.
  • Royal Bank of Canada first reported a position in Clarus Therapeutics Holdings, Inc. Common Stock in Q1 2021 and held it in 4 quarters.
  • Royal Bank of Canada's Clarus Therapeutics Holdings, Inc. Common Stock position peaked at $19K in Q1 2021.
  • 25 funds tracked by Wall St. Rank held Clarus Therapeutics Holdings, Inc. Common Stock as of Q2 2022.

Based on Royal Bank of Canada's 13F filing for Q2 2022, filed 15 Aug 2022.